XIN YUAN ENT received resumption guidance from the Stock Exchange
XIN YUAN ENT received the resumption guidance from the Stock Exchange, requiring an independent investigation, the release of unpublished financial performance, proof of management's integrity and capability, an internal control review, compliance with listing rules, and informing the market of important information, so that shareholders and investors can assess the company's condition
According to the announcement from XIN YUAN ENT (01748), the company received a letter from the Stock Exchange on May 26, 2025, which listed the following resumption guidelines for the trading of its shares:
(a) Conduct an appropriate independent forensic investigation into the complaint letter purportedly issued in the names of two shareholders and each allegation in the announcement (the allegations), assess their truthfulness, accuracy, substance, and impact on the company's business operations and financial condition, publish the investigation results, and take appropriate remedial measures;
(b) Publish all unpublished financial results in accordance with the listing rules and address any audit modifications;
(c) Demonstrate that the integrity, capability, and/or character of the group's management and any individuals with significant influence over the company's management and operations do not raise reasonable regulatory concerns that could pose risks to investors and undermine market confidence;
(d) Conduct an independent internal control review and demonstrate that the company has established adequate internal controls and procedures to meet its responsibilities under the listing rules;
(e) Demonstrate compliance with Rule 13.24;
(f) Inform the market of all material information to enable the company's shareholders and other investors to assess the company's condition
